US Capitol Capsule: US anti-bribery actions 'next shoe' in China scandal?

Drug makers embroiled in the recent bribery allegations in China are likely sweating over whether the next shoe to drop will be US charges under the Foreign Corrupt Practices Act (FCPA), given the Security and Exchange Commission (SEC) has not been shy in going after publicly traded biopharmas the agency determines has violated the law.